These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33798735)

  • 1. Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin.
    Barbolina MV
    Pharmacol Res; 2021 Jun; 168():105585. PubMed ID: 33798735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Tau protein in resistance to paclitaxel.
    Smoter M; Bodnar L; Duchnowska R; Stec R; Grala B; Szczylik C
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):553-7. PubMed ID: 21713447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
    Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
    Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on taxane development: new analogs and new formulations.
    Yared JA; Tkaczuk KH
    Drug Des Devel Ther; 2012; 6():371-84. PubMed ID: 23251087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
    Baquero MT; Lostritto K; Gustavson MD; Bassi KA; Appia F; Camp RL; Molinaro AM; Harris LN; Rimm DL
    Breast Cancer Res; 2011 Nov; 13(5):R85. PubMed ID: 21888627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
    Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
    J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting and Overcoming Taxane Chemoresistance.
    Rodrigues-Ferreira S; Moindjie H; Haykal MM; Nahmias C
    Trends Mol Med; 2021 Feb; 27(2):138-151. PubMed ID: 33046406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
    Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
    Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
    Rowinsky EK
    Annu Rev Med; 1997; 48():353-74. PubMed ID: 9046968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive and Prognostic Value of the TauProtein in Breast Cancer.
    Bonneau C; Gurard-Levin ZA; Andre F; Pusztai L; Rouzier R
    Anticancer Res; 2015 Oct; 35(10):5179-84. PubMed ID: 26408675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes, microtubules and chemoresistant breast cancer.
    McGrogan BT; Gilmartin B; Carney DN; McCann A
    Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
    Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
    Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.